Shares of 23andMe Holding Co. (NASDAQ:ME – Get Rating) gapped up before the market opened on Monday . The stock had previously closed at 2.21, but opened at 2.33. 23andMe shares last traded at 2.16, with a volume of 78,887 shares changing hands.
Several research firms have recently weighed in on ME. Credit Suisse Group reduced their price objective on 23andMe from $11.00 to $7.00 and set an “outperform” rating for the company in a research note on Friday, May 27th. Citigroup cut their price objective on 23andMe from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Friday, May 27th.
The firm has a market capitalization of $1.02 billion, a P/E ratio of -3.56 and a beta of 1.45. The business has a 50 day moving average price of 2.99 and a 200 day moving average price of 4.55.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC boosted its holdings in shares of 23andMe by 13.1% in the 1st quarter. Virtu Financial LLC now owns 102,378 shares of the company’s stock worth $392,000 after acquiring an additional 11,819 shares in the last quarter. Prescott General Partners LLC boosted its holdings in shares of 23andMe by 26.0% in the 1st quarter. Prescott General Partners LLC now owns 1,423,829 shares of the company’s stock worth $5,453,000 after acquiring an additional 293,450 shares in the last quarter. Salem Investment Counselors Inc. acquired a new position in shares of 23andMe in the 1st quarter worth approximately $38,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of 23andMe in the 1st quarter worth approximately $50,000. Finally, Ensign Peak Advisors Inc boosted its holdings in shares of 23andMe by 340.5% in the 1st quarter. Ensign Peak Advisors Inc now owns 30,040 shares of the company’s stock worth $115,000 after acquiring an additional 23,220 shares in the last quarter. 14.14% of the stock is currently owned by institutional investors and hedge funds.
About 23andMe (NASDAQ:ME)
23andMe Holding Co operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
Featured Stories
- Get a free copy of the StockNews.com research report on 23andMe (ME)
- Where Are Interest Rates Going This Year? A Lot Higher
- Doximity Stock is an Interesting Healthcare Play
- Atlassian Stock: Taking Another Look
- SunPower Stock is a Value Solar Play
- The Analysts Rip The Seams Out Of Stitch Fix
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.